- Home
- BLIN vs IMRN Comparison
BLIN vs IMRN Comparison
Compare BLIN & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- IMRN
- Stock Information
- Founded
- BLIN 2000
- IMRN 1994
- Country
- BLIN United States
- IMRN Australia
- Employees
- BLIN N/A
- IMRN N/A
- Industry
- BLIN EDP Services
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- IMRN Health Care
- Exchange
- BLIN Nasdaq
- IMRN Nasdaq
- Market Cap
- BLIN 14.1M
- IMRN 15.0M
- IPO Year
- BLIN 2007
- IMRN N/A
- Fundamental
- Price
- BLIN $1.53
- IMRN $2.11
- Analyst Decision
- BLIN Hold
- IMRN Strong Buy
- Analyst Count
- BLIN 1
- IMRN 1
- Target Price
- BLIN N/A
- IMRN $5.00
- AVG Volume (30 Days)
- BLIN 121.3K
- IMRN 6.2K
- Earning Date
- BLIN 02-12-2025
- IMRN 12-31-2024
- Dividend Yield
- BLIN N/A
- IMRN N/A
- EPS Growth
- BLIN N/A
- IMRN N/A
- EPS
- BLIN N/A
- IMRN N/A
- Revenue
- BLIN $15,293,000.00
- IMRN $3,271,194.00
- Revenue This Year
- BLIN N/A
- IMRN N/A
- Revenue Next Year
- BLIN $6.35
- IMRN N/A
- P/E Ratio
- BLIN N/A
- IMRN N/A
- Revenue Growth
- BLIN N/A
- IMRN 171.67
- 52 Week Low
- BLIN $0.75
- IMRN $1.59
- 52 Week High
- BLIN $1.60
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- BLIN 63.98
- IMRN 52.87
- Support Level
- BLIN $1.25
- IMRN $2.05
- Resistance Level
- BLIN $1.43
- IMRN $2.23
- Average True Range (ATR)
- BLIN 0.10
- IMRN 0.16
- MACD
- BLIN 0.01
- IMRN 0.02
- Stochastic Oscillator
- BLIN 66.78
- IMRN 47.06
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.